Division of Neurology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Department of Physical Therapy, Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan.
JAMA Netw Open. 2022 Sep 1;5(9):e2232571. doi: 10.1001/jamanetworkopen.2022.32571.
Although influenza vaccination has been associated with Guillain-Barré syndrome (GBS), the findings among studies of older adult populations are inconsistent.
To determine the risk of GBS after influenza vaccination among older adults.
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study incorporated a self-controlled case series design. Days 1 to 7, days 1 to 14, and days 1 to 42 after influenza vaccination were identified as risk intervals; days 8 to 180, days 15 to 180, and days 43 to 180 comprised the corresponding control interval. Population-based data were obtained from Taiwan's National Health Insurance research database between January 1, 2003, and December 31, 2017. Data were analyzed from November 1, 2021, through February 28, 2022. Adults 65 years or older who developed GBS within 180 days after influenza vaccination were enrolled.
Government-funded seasonal influenza vaccination.
Onset of GBS during risk intervals after influenza vaccination compared with control intervals using Poisson regression to calculate incidence rate ratio (IRR).
Of 13 482 122 adults aged 65 years or older who received an influenza vaccination, 374 were hospitalized for GBS. The mean (SD) age of the study population was 75.0 (6.1) years; 215 (57.5%) were men and 159 (42.5%) were women. In terms of comorbidities, 33 adults (8.8%) had cancer and 4 (1.1%) had autoimmune diseases. The IRRs for GBS during days 1 to 7, days 1 to 14, and days 1 to 42 were 0.95 (95% CI, 0.55-1.61; P = .84), 0.87 (95% CI, 0.58-1.29; P = .48), and 0.92 (95% CI, 0.72-1.17; P = .49), respectively. No results showed statistical significance. Similarly, no significant differences in IRRs were noted for the overall risk interval (ie, days 1-42) in subgroup analyses pertaining to different age groups (65-74 years [0.93 (95% CI, 0.66-1.31)], 75-84 years [0.85 (95% CI, 0.58-1.26)], and ≥85 years [1.10 (95% CI, 0.57-2.11)]), sex (men, 0.97 [95% CI, 0.71-1.33; P = .87]; women, 0.85 [95% CI, 0.58-1.23; P = .39]), Charlson Comorbidity Index (1.03 [95% CI, 0.77-1.38; P = .84]), or comorbidities (cancer, 0.68 [95% CI, 0.28-1.64; P = .39]; autoimmune disease, 1.10 [95% CI, 0.11-10.53; P = .94]).
These findings suggest that influenza vaccination did not increase the risk of GBS among adults aged 65 years or older in Taiwan regardless of postvaccination period or underlying characteristics.
虽然流感疫苗接种与吉兰-巴雷综合征(GBS)有关,但在老年人群体的研究结果并不一致。
确定老年人接种流感疫苗后发生 GBS 的风险。
设计、地点和参与者:这项横断面研究采用了自我对照病例系列设计。将接种流感疫苗后的第 1 至 7 天、第 1 至 14 天和第 1 至 42 天定为风险间隔期;第 8 至 180 天、第 15 至 180 天和第 43 至 180 天为相应的对照间隔期。基于人群的数据来自台湾 2003 年 1 月 1 日至 2017 年 12 月 31 日的全民健康保险研究数据库。数据分析于 2021 年 11 月 1 日至 2022 年 2 月 28 日进行。在接种流感疫苗后 180 天内发生 GBS 的 65 岁或以上成年人被纳入研究。
政府资助的季节性流感疫苗接种。
使用泊松回归计算流感疫苗接种后风险间隔期与对照间隔期相比的 GBS 发病风险比(IRR)。
在接种流感疫苗的 13482122 名 65 岁或以上成年人中,有 374 人因 GBS 住院。研究人群的平均(SD)年龄为 75.0(6.1)岁;215 人(57.5%)为男性,159 人(42.5%)为女性。就合并症而言,33 人(8.8%)患有癌症,4 人(1.1%)患有自身免疫性疾病。接种后第 1 至 7 天、第 1 至 14 天和第 1 至 42 天的 GBS 的 IRR 分别为 0.95(95%CI,0.55-1.61;P=0.84)、0.87(95%CI,0.58-1.29;P=0.48)和 0.92(95%CI,0.72-1.17;P=0.49)。没有结果显示统计学意义。同样,在不同年龄组(65-74 岁[0.93(95%CI,0.66-1.31)]、75-84 岁[0.85(95%CI,0.58-1.26)]和≥85 岁[1.10(95%CI,0.57-2.11)])、性别(男性 0.97(95%CI,0.71-1.33;P=0.87);女性 0.85(95%CI,0.58-1.23;P=0.39)]、Charlson 合并症指数(1.03(95%CI,0.77-1.38;P=0.84))或合并症(癌症 0.68(95%CI,0.28-1.64;P=0.39);自身免疫性疾病 1.10(95%CI,0.11-10.53;P=0.94))亚组分析中,也未观察到 IRR 的显著差异。
这些发现表明,在台湾,无论接种后时间或潜在特征如何,流感疫苗接种都不会增加 65 岁及以上成年人患 GBS 的风险。